Limits...
Melatonin and female hormone secretion in postmenopausal overweight women.

Walecka-Kapica E, Chojnacki J, Stępień A, Wachowska-Kelly P, Klupińska G, Chojnacki C - Int J Mol Sci (2015)

Bottom Line: No significant correlation was found in all groups between the level of melatonin and the levels of estradiol and FSH.A negative correlation was found between aMT6s excretion and BMI, and a positive correlation between the level of FSH and BMI, mainly in overweight women.The obtained results indicate a significant effect of melatonin deficiency on the process of weight gain in postmenopausal women and justify its use in treatment of these disorders.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University, 1 Haller's Square, 90-647 Lodz, Poland. ewa.walecka-kapica@umed.lodz.pl.

ABSTRACT
Estrogen deficiency is considered to be the main cause of increased appetite and increased weight in postmenopausal women. In this period, reduced secretion of melatonin (MEL) was also observed. The aim of the study was to evaluate the secretion of melatonin, 17-β estradiol and follicle-stimulating hormone (FSH) in relation to body mass index (BMI) in pre- and postmenopausal women. The study included 90 women divided into three equal groups: group I (control)-women without menstrual disorders, group II-postmenopausal women without change in appetite and body weight, group III-postmenopausal women experiencing increased appetite and weight gain. In each patient, serum melatonin, 17-β-estradiol, FSH and urine a 6-sulfatoxymelatonin (aMT6s) were determined. Compared to the control group, the level of melatonin and estradiol was statistically lower. The FSH level was higher than in the groups of postmenopausal women. No significant correlation was found in all groups between the level of melatonin and the levels of estradiol and FSH. A negative correlation was found between aMT6s excretion and BMI, and a positive correlation between the level of FSH and BMI, mainly in overweight women. The obtained results indicate a significant effect of melatonin deficiency on the process of weight gain in postmenopausal women and justify its use in treatment of these disorders.

Show MeSH

Related in: MedlinePlus

The level of estradiol in group I 49.16 ± 19.80 pg/mL, group II 15.49 ± 6.33 pg/mL, group III 19.01 ± 3.87 pg/mL; they are the significant differences in mean value between group I and II; group I and III; *** p < 0.001.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4307288&req=5

ijms-16-01030-f003: The level of estradiol in group I 49.16 ± 19.80 pg/mL, group II 15.49 ± 6.33 pg/mL, group III 19.01 ± 3.87 pg/mL; they are the significant differences in mean value between group I and II; group I and III; *** p < 0.001.

Mentions: Significantly greater differences were obtained in the results of the tests of female hormones. The level of estradiol was in groups I, II and III respectively: 49.16 ± 19.80 pg/mL, 15.49 ± 6.33 pg/mL (p < 0.001) and 19.01 ± 3.87 pg/mL (p < 0.001; Figure 3).


Melatonin and female hormone secretion in postmenopausal overweight women.

Walecka-Kapica E, Chojnacki J, Stępień A, Wachowska-Kelly P, Klupińska G, Chojnacki C - Int J Mol Sci (2015)

The level of estradiol in group I 49.16 ± 19.80 pg/mL, group II 15.49 ± 6.33 pg/mL, group III 19.01 ± 3.87 pg/mL; they are the significant differences in mean value between group I and II; group I and III; *** p < 0.001.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4307288&req=5

ijms-16-01030-f003: The level of estradiol in group I 49.16 ± 19.80 pg/mL, group II 15.49 ± 6.33 pg/mL, group III 19.01 ± 3.87 pg/mL; they are the significant differences in mean value between group I and II; group I and III; *** p < 0.001.
Mentions: Significantly greater differences were obtained in the results of the tests of female hormones. The level of estradiol was in groups I, II and III respectively: 49.16 ± 19.80 pg/mL, 15.49 ± 6.33 pg/mL (p < 0.001) and 19.01 ± 3.87 pg/mL (p < 0.001; Figure 3).

Bottom Line: No significant correlation was found in all groups between the level of melatonin and the levels of estradiol and FSH.A negative correlation was found between aMT6s excretion and BMI, and a positive correlation between the level of FSH and BMI, mainly in overweight women.The obtained results indicate a significant effect of melatonin deficiency on the process of weight gain in postmenopausal women and justify its use in treatment of these disorders.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University, 1 Haller's Square, 90-647 Lodz, Poland. ewa.walecka-kapica@umed.lodz.pl.

ABSTRACT
Estrogen deficiency is considered to be the main cause of increased appetite and increased weight in postmenopausal women. In this period, reduced secretion of melatonin (MEL) was also observed. The aim of the study was to evaluate the secretion of melatonin, 17-β estradiol and follicle-stimulating hormone (FSH) in relation to body mass index (BMI) in pre- and postmenopausal women. The study included 90 women divided into three equal groups: group I (control)-women without menstrual disorders, group II-postmenopausal women without change in appetite and body weight, group III-postmenopausal women experiencing increased appetite and weight gain. In each patient, serum melatonin, 17-β-estradiol, FSH and urine a 6-sulfatoxymelatonin (aMT6s) were determined. Compared to the control group, the level of melatonin and estradiol was statistically lower. The FSH level was higher than in the groups of postmenopausal women. No significant correlation was found in all groups between the level of melatonin and the levels of estradiol and FSH. A negative correlation was found between aMT6s excretion and BMI, and a positive correlation between the level of FSH and BMI, mainly in overweight women. The obtained results indicate a significant effect of melatonin deficiency on the process of weight gain in postmenopausal women and justify its use in treatment of these disorders.

Show MeSH
Related in: MedlinePlus